Sayfa 2 - Swedish (OMX) Büyüme Hisse Senetleri Healthcare

Name: Financial Insights Based on S&P Global Market Intelligence
Creator: Simply Wall St Pty Ltd
License: https://www.spglobal.com/content/dam/spglobal/corporate/en/documents/secure/MI-FastTrack-Terms-and-Conditions-July-2023.pdf

GÜNCELLENDİ Jun 10, 2026

Swedish Healthcare Büyüme Hisse Senetlerini üzerinde olan OMX keşfedin. Tahmini büyümeye göre sıralanan bu Healthcare Stocks diğer şirketlere kıyasla beklenenden daha yüksek kazanç veya satış büyümesine sahiptir.

79 şirketler

Şirket	Son Fiyat	7D Dönüş	1Y Dönüş	Piyasa Değeri	Analistlerin Hedefi	Değerleme	Büyüme	Bölünmüş Verim
SECT B	SEK 312.20	9.3%	-5.7%	SEK 60.2b	SEK 336.67	106.7	23.7%	0.7%
IMMNOV	SEK 0.18	-8.4%	-59.4%	SEK 123.2m	n/a	135.7	23.5%	n/a
RAY B	SEK 220.00	2.1%	-32.0%	SEK 7.5b	SEK 330.00	33.6	22.6%	1.8%
STIL	SEK 266.00	3.9%	26.7%	SEK 2.4b	SEK 287.00	38.6	22.4%	0%
ARJO B	SEK 24.50	1.1%	-26.3%	SEK 6.7b	SEK 30.00	19.0	21.3%	3.9%
HUM	SEK 49.75	3.4%	35.4%	SEK 2.4b	SEK 62.50	11.8	20.8%	2.7%
ASKER	SEK 78.00	1.0%	-27.6%	SEK 29.9b	SEK 96.20	47.8	17.9%	0.5%
CEVI	SEK 126.00	4.3%	-36.7%	SEK 3.0b	SEK 179.00	22.4	15.0%	2.2%
AMBEA	SEK 140.40	3.2%	26.6%	SEK 11.2b	SEK 181.00	15.8	11.9%	1.9%
GETI B	SEK 190.25	0.7%	-0.4%	SEK 51.8b	SEK 224.70	22.0	11.8%	2.5%
ATT	SEK 116.50	7.1%	92.6%	SEK 16.7b	SEK 125.00	19.0	8.0%	1.5%
IMP A SDB	SEK 56.60	-2.4%	41.0%	SEK 16.0b	SEK 72.72	668.6	-4.0%	n/a
ICO	SEK 1.25	5.0%	-32.4%	SEK 120.2m	n/a	8.7	-7.6%	n/a
QCORE	SEK 0.38	-15.2%	-56.8%	SEK 16.3m	n/a	0.4	n/a	n/a
INTEG B	SEK 8.08	3.1%	-63.0%	SEK 215.5m	n/a	2.2	n/a	n/a
FLUI	SEK 33.50	-30.6%	216.0%	SEK 46.0m	n/a	2.3	n/a	n/a
2CUREX	SEK 1.76	-3.3%	-64.4%	SEK 44.2m	n/a	n/a	n/a	4.8%
PRLD	SEK 13.34	-4.0%	-42.7%	SEK 160.7m	n/a	3.3	n/a	n/a
REDS	SEK 5.70	-1.7%	-18.6%	SEK 93.7m	n/a	2.9	n/a	0%
LUMITO	SEK 2.50	25.0%	-98.9%	SEK 8.6m	n/a	0.1	n/a	n/a
SIN	SEK 3.32	-5.1%	n/a	SEK 146.6m	n/a	1.2	n/a	n/a
S2M	SEK 0.0054	-3.6%	-72.3%	SEK 4.9m	n/a	0.5	n/a	n/a
H100	SEK 1.23	0.7%	-73.5%	SEK 416.2m	n/a	35.2	n/a	n/a
ORTI B	SEK 1.86	-2.1%	42.1%	SEK 164.5m	n/a	2.1	n/a	n/a

Page 2 of 4